Anti-Tau Antibodies and methods of use
AssigneesGenentech, Inc., AC Immune SA
InventorsOskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
Life of this patent
Estimating the term…
Abstract
The invention provides anti-Tau antibodies and methods of using the same.
Claims78
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises:
- a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 342;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 343;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 344;
- HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:
- 345, 15, 468 to 478, 495 to 517, 522 to 534, 536 to 539, and 543 to 556;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 346;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 347;
- b) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 72;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 73;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 74;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 75;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 76;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 77;
- c) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 42;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 43;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 44;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 45;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 46;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 47;
- d) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 62;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 63;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 64;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 65;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 66;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 67;
- e) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 212;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 213;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 214;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 215;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 216;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 217;
- f) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 32;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 33;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 34;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 35;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 36;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 37;
- or
- g) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 52;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 53;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 54;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 55;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 56;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 57.
A method of reducing the level of Tau protein, non-phosphorylated Tau protein, phosphorylated Tau protein, or hyperphosphorylated Tau protein in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises:
- a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 342;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 343;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 344;
- HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:
- 345, 15, 468 to 478, 495 to 517, 522 to 534, 536 to 539, and 543 to 556;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 346;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 347;
- b) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 72;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 73;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 74;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 75;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 76;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 77;
- c) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 42;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 43;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 44;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 45;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 46;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 47;
- d) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 62;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 63;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 64;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 65;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 66;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 67;
- e) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 212;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 213;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 214;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 215;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 216;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 217;
- f) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 32;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 33;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 34;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 35;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 36;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 37;
- or
- g) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 52;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 53;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 54;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 55;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 56;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 57.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 342;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 343;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 344;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 345;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 346;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 347.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering monoclonal antibody that binds to human Tau, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 340 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 341.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 348 or SEQ ID NO:
- 602 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 349.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO:
- 348 or SEQ ID NO:
- 602 and a light chain consisting of the amino acid sequence of SEQ ID NO:
- 349.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 342;
- HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 343;
- HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 344;
- HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 345;
- HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 346;
- and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 347, wherein the antibody is an IgG4 antibody, and wherein the antibody comprises S228P, M252Y, S254T, and T256E mutations.
A method of retaining or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering a monoclonal antibody that binds to human Tau, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 340 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 341, wherein the antibody is an IgG4 antibody, and wherein the antibody comprises S228P, M252Y, S254T, and T256E mutations.
Dependencies are inferred from the claim text.